Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Olumiant
|
| gptkbp:activities |
gptkb:Janus_kinase_(JAK)_inhibitor
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
gptkb:Olumiant
|
| gptkbp:clinical_trial |
Phase 3
autoimmune diseases COVID-19 clinical trials RA clinical trials |
| gptkbp:composed_of |
gptkb:chemical_compound
|
| gptkbp:contraindication |
active infections
severe liver impairment |
| gptkbp:developed_by |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:duration |
long-term use possible
short-term use recommended for COVID-19 |
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
film-coated tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
baricitinib
|
| gptkbp:indication |
moderate to severe rheumatoid arthritis
|
| gptkbp:ingredients |
C16 H17 N7 O3
|
| gptkbp:interacts_with |
immunosuppressants
live vaccines other JAK inhibitors |
| gptkbp:invention |
patented
|
| gptkbp:is_used_for |
treatment of rheumatoid arthritis
|
| gptkbp:lifespan |
12 hours
|
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
gptkb:2018
|
| gptkbp:metabolism |
liver
|
| gptkbp:population |
adults
children (off-label use) |
| gptkbp:provides_information_on |
EULAR guidelines
ACR guidelines |
| gptkbp:research_areas |
gptkb:drug
inflammatory diseases |
| gptkbp:safety_features |
liver function tests
lipid levels blood counts |
| gptkbp:side_effect |
headache
nausea gastrointestinal perforation blood clots thrombosis increased risk of infections increased liver enzymes elevated cholesterol |
| gptkbp:storage |
room temperature
|
| gptkbp:treatment |
hospitalization reduction in COVID-19
improved symptoms in RA mortality reduction in COVID-19 reduced disease activity in RA |